Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
暂无分享,去创建一个
[1] A D Oxman,et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. , 2006, The Cochrane database of systematic reviews.
[2] Xuan Yu,et al. Pharmaceutical supply chain in China: current issues and implications for health system reform. , 2010, Health policy.
[3] Anders Anell,et al. Deregulating the pharmacy market: the case of Iceland and Norway. , 2005, Health policy.
[4] S. Morgan,et al. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. , 2004, Health policy.
[5] Y. R. Wang,et al. The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s , 2003, Health economics.
[6] S. Schneeweiss. Reference drug programs: effectiveness and policy implications. , 2007, Health policy.
[7] M. Mrazek. Comparative approaches to pharmaceutical price regulation in the European Union. , 2002, Croatian medical journal.
[8] J. Mauskopf. Value in health: "bridging the gap" among our disciplines. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] J. M. Traulsen,et al. Cost-Containment as Part of Pharmaceutical Policy , 2005, Pharmacy World and Science.
[10] S. Strøm,et al. Price regulation and generic competition in the pharmaceutical market , 2006, The European Journal of Health Economics.
[11] P. Souverein,et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. , 2007, British journal of clinical pharmacology.
[12] L. Garrison,et al. The drug budget silo mentality in Europe: an overview. , 2003, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] L. Garattini,et al. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. , 2007, Health policy.
[14] J. Avorn,et al. Pharmaceutical cost containment with reference-based pricing: time for refinements. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[15] J. McNeil,et al. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. , 2002, PharmacoEconomics.
[16] J. Sverre,et al. Pricing and reimbursement of pharmaceuticals in Norway , 2002, The European Journal of Health Economics.
[17] M. Dickson,et al. Pharmaceutical reference prices. How do they work in practice? , 1998, PharmacoEconomics.
[18] P. Grootendorst,et al. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. , 2006, Health economics.
[19] S. Simoens. International comparison of generic medicine prices , 2007, Current medical research and opinion.
[20] P. Norris. The impact of European harmonisation on Norwegian drug policy. , 1998, Health policy.
[21] Pricing and Reimbursement of Pharmaceuticals. A New Culture for the Community Pharmacist. , 1998, Pharmacy World and Science.
[22] F. Andersson. Norway's pivotal role in regulatory health economics and pharmaceutical cost containment--what can other countries learn? , 1992, Health policy.
[23] J. Puig-Junoy,et al. Review of the literature on reference pricing. , 2000, Health policy.
[24] J. Lexchin. A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. , 2006, Health Policy.
[25] S. Brophy,et al. Interventions for latent autoimmune diabetes (LADA) in adults. , 2011, The Cochrane database of systematic reviews.